Literature DB >> 18460263

Osteonecrosis of the jaw.

Philip N Sambrook1, Peter Ebeling.   

Abstract

Bisphosphonates are effective therapy for osteoporosis, Paget's disease, and metastatic bone disease. Generally, the side effects of bisphosphonates are minimal. Recently, an uncommon adverse reaction affecting the maxilla or mandible, called osteonecrosis of the jaw, has been reported, especially in those patients receiving high doses of bisphosphonates in the oncology setting. Regarding doses used to treat osteoporosis, clinicians must keep the very small potential absolute risk of jaw osteonecrosis in perspective and consider it in relation to the demonstrated benefit of bisphosphonates. Still, in a very small number of patients taking bisphosphonates, intractable, painful, nonhealing exposed bone may occur following dental extractions or denture irritation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460263     DOI: 10.1007/s11926-008-0018-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  30 in total

1.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

2.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  Patrick M Purcell; Ian W Boyd
Journal:  Med J Aust       Date:  2005-04-18       Impact factor: 7.738

3.  Adverse oral sequelae to bisphosphonate administration.

Authors:  Mark Marunick; Robert Miller; Sara Gordon
Journal:  J Mich Dent Assoc       Date:  2005-11

4.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  Philip Sambrook; Ian Olver; Alastair Goss
Journal:  Aust Fam Physician       Date:  2006-10

5.  Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

Authors:  M Ardine; D Generali; M Donadio; S Bonardi; M Scoletta; A M Vandone; M Mozzati; O Bertetto; A Bottini; L Dogliotti; A Berruti
Journal:  Ann Oncol       Date:  2006-03-08       Impact factor: 32.976

6.  Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report.

Authors:  W J Starck; B N Epker
Journal:  Int J Oral Maxillofac Implants       Date:  1995 Jan-Feb       Impact factor: 2.804

7.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

8.  Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.

Authors:  D Aguiar Bujanda; U Bohn Sarmiento; M A Cabrera Suárez; J Aguiar Morales
Journal:  Ann Oncol       Date:  2006-11-02       Impact factor: 32.976

9.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

10.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

View more
  4 in total

1.  Osteonecrosis of the jaw in patient with denosumab therapy.

Authors:  Sergio Olate; Francisca Uribe; Felipe Martinez; Andrés Almeida; Alejandro Unibazo
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 2.  For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases.

Authors:  Stavros C Manolagas; A Michael Parfitt
Journal:  Bone       Date:  2012-09-23       Impact factor: 4.398

3.  Oral lesions and lymphoproliferative disorders.

Authors:  P Castellarin; G Pozzato; G Tirelli; R Di Lenarda; M Biasotto
Journal:  J Oncol       Date:  2010-09-01       Impact factor: 4.375

4.  Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.

Authors:  Alex Fisher; Jodie Martin; Wichat Srikusalanukul; Michael Davis
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.